Please login to the form below

Not currently logged in

Genzyme appoints MS and rare diseases business leaders

William Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases

Genzyme has appointed leaders for its core multiple sclerosis and rare diseases businesses.

William “Bill” Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases.

“These appointments are a critical step in launching the new Genzyme,” said the company's CEO David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”

Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.

He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

Vivaldi has been with Genzyme since 1997 and was most recently president of Genzyme's renal and endocrinology business. He previously served as senior vice president and president of Genzyme Latin America.

11th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Body image and mental health: The psoriasis connection
As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
It’s not the end of the world, is it?
Industry change isn’t always gradual – it can be apocalyptic...